42 research outputs found

    Bicistronic DNA vaccines simultaneously encoding HIV, HSV and HPV antigens promote CD8⁺ T cell responses and protective immunity

    Get PDF
    Millions of people worldwide are currently infected with human papillomavirus (HPV), herpes simplex virus (HSV) or human immunodeficiency virus (HIV). For this enormous contingent of people, the search for preventive and therapeutic immunological approaches represents a hope for the eradication of latent infection and/or virus-associated cancer. To date, attempts to develop vaccines against these viruses have been mainly based on a monovalent concept, in which one or more antigens of a virus are incorporated into a vaccine formulation. In the present report, we designed and tested an immunization strategy based on DNA vaccines that simultaneously encode antigens for HIV, HSV and HPV. With this purpose in mind, we tested two bicistronic DNA vaccines (pIRES I and pIRES II) that encode the HPV-16 oncoprotein E7 and the HIV protein p24 both genetically fused to the HSV-1 gD envelope protein. Mice i.m. immunized with the DNA vaccines mounted antigen-specific CD8⁺ T cell responses, including in vivo cytotoxic responses, against the three antigens. Under experimental conditions, the vaccines conferred protective immunity against challenges with a vaccinia virus expressing the HIV-derived protein Gag, an HSV-1 virus strain and implantation of tumor cells expressing the HPV-16 oncoproteins. Altogether, our results show that the concept of a trivalent HIV, HSV, and HPV vaccine capable to induce CD8⁺ T cell-dependent responses is feasible and may aid in the development of preventive and/or therapeutic approaches for the control of diseases associated with these viruses.CNPqINCTVFAPESPUS

    Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

    Get PDF
    Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

    Immune Response of Calves Vaccinated with <i>Brucella abortus</i> S19 or RB51 and Revaccinated with RB51

    No full text
    <div><p><i>Brucella abortus</i> S19 and RB51 strains have been successfully used to control bovine brucellosis worldwide; however, currently, most of our understanding of the protective immune response induced by vaccination comes from studies in mice. The aim of this study was to characterize and compare the immune responses induced in cattle prime-immunized with <i>B</i>. <i>abortus</i> S19 or RB51 and revaccinated with RB51. Female calves, aged 4 to 8 months, were vaccinated with either vaccine S19 (0.6–1.2 x 10<sup>11</sup> CFU) or RB51 (1.3 x 10<sup>10</sup> CFU) on day 0, and revaccinated with RB51 (1.3 x 10<sup>10</sup> CFU) on day 365 of the experiment. Characterization of the immune response was performed using serum and peripheral blood mononuclear cells. Blood samples were collected on days 0, 28, 210, 365, 393 and 575 post-immunization. Results showed that S19 and RB51 vaccination induced an immune response characterized by proliferation of CD4<sup>+</sup> and CD8<sup>+</sup> T-cells; IFN-ɣ and IL-17A production by CD4<sup>+</sup> T-cells; cytotoxic CD8<sup>+</sup> T-cells; IL-6 secretion; CD4<sup>+</sup> and CD8<sup>+</sup> memory cells; antibodies of IgG1 class; and expression of the phenotypes of activation in T-cells. However, the immune response stimulated by S19 compared to RB51 showed higher persistency of IFN-ɣ and CD4<sup>+</sup> memory cells, induction of CD21<sup>+</sup> memory cells and higher secretion of IL-6. After RB51 revaccination, the immune response was chiefly characterized by increase in IFN-ɣ expression, proliferation of antigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cells, cytotoxic CD8<sup>+</sup> T-cells and decrease of IL-6 production in both groups. Nevertheless, a different polarization of the immune response, CD4<sup>+</sup>- or CD8<sup>+</sup>-dominant, was observed after the booster with RB51 for S19 and RB51 prime-vaccinated animals, respectively. Our results indicate that after prime vaccination both vaccine strains induce a strong and complex Th1 immune response, although after RB51 revaccination the differences between immune profiles induced by prime-vaccination become accentuated.</p></div

    IFN-ɣ and IL-17A production by CD4<sup>+</sup> and CD8<sup>+</sup> T-cell subsets in peripheral blood mononuclear cells of S19 and RB51 prime vaccinated, and RB51 revaccinated cattle upon <i>in vitro</i> stimulation with ɣ-irradiated <i>B</i>. <i>abortus</i> 2308.

    No full text
    <p>Tendency (median) (a) and box plot (median, first and third quartiles) (b) charts of the results. Whiskers show the lower and upper 1.5 interquartile range. Vaccinations were indicated by arrows. Significant differences (P < 0.05) between vaccination regimens (on same day) are indicated by uppercase letters (Mann-Whitney-test), and lowercase letters indicate statistical difference between days in same group (Skillings Mack test followed by Wilcoxon signed rank test).</p

    Experimental design.

    No full text
    <p>Forty crossbred females calves aged between 4 to 8 months were divided in two experimental groups: group S19—composed of 20 calves vaccinated with S19 vaccine strain (0.6–1.2 x 10<sup>11</sup> CFU) at day 0 of the experiment; and group RB51—composed of 20 calves vaccinated with RB51 vaccine strain (1.3 x 10<sup>10</sup> CFU) at day 0 of the experiment. Both groups were revaccinated with RB51 (1.3 x 10<sup>10</sup> CFU) at day 365 of the experiment. The number of animals tested in each immunological assessment (0,28, 210, 365, 393 and 575) are shown in the rectangles. The days when the vaccinations occurred are highlighted with arrows.</p
    corecore